DelveInsight’s Chronic Lower Back Pain (CLBP) market report provides thorough comprehension of Chronic Lower Back Pain (CLBP), historical and forecasted epidemiology, and Chronic Lower Back Pain (CLBP) market trends in the 7MM (the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan).
Some of the Important Findings from the Chronic Lower Back Pain Market Report
- As per DelveInsight’s Chronic Lower Back Pain epidemiology insights, the total prevalent population was estimated to be over 75 million in the 7MM in 2020.
- Among the EU5 countries, the UK has the highest CLBP diagnosed prevalent population whereas Spain had the lowest in 2020.
- According to DelveInsight, the CLBP diagnosed prevalence is higher in females as compared to males in the 7MM in 2020 except Japan.
- Key companies across the globe such as Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Stayble Therapeutics, AnGes MG, and others are diligently working toward the development of novel therapies for Chronic Lower Back Pain treatment.
- Key pipeline therapies such as Buprenorphine, Egalet-002, Tanezumab, Rexlemestrocel-L, Fasinumab, AXS-02, ALLOD-2, ASP7962, ARRY-954, and others are ready to enter the Chronic Lower Back Pain market.
- Buprenorphine (Braeburn Pharmaceuticals/Camurus) is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. It is being evaluated in Phase III clinical trials for opioid use disorder, chronic pain, and chronic lower back pain.
- Tanezumab (Pfizer/Eli Lilly and Company) is a first-in-class non-opioid treatment that works by targeting, binding to, and inhibiting nerve growth factor (NGF). It is being evaluated in Phase III clinical trials for CLBP. The US FDA has granted Fast Track designation to Tanezumabfor the treatment of chronic pain in patients with osteoarthritis (OA) and chronic lower back pain (CLBP).
- Egalet-002 (Egalet Corporation) is a pure opioid that functions as an opioid mu and kappa agonist as well as an opioid delta agonist. The US Food and Drug Administration has granted Fast Track Designation to Egalet-002.
Want to learn more? Request for sample @ Chronic Lower Back Pain Market Outlook
The Chronic Lower Back Pain (CLBP) market report covers current treatment practices, emerging drugs, and market share of individual therapies, as well as the current and projected 7MM Chronic Lower Back Pain (CLBP) market size from 2018 to 2030.
Chronic Lower Back Pain: Overview
Chronic Lower Back Pain (CLBP) is pain that lasts for at least 12 weeks after an initial injury or underlying cause of acute low back pain has been treated. Low back pain is common, and everyone has experienced it at some point; however, the exact cause of lower back pain is unknown. Clinicians should inquire about pain onset, severity, chronicity, and other factors such as pain experience when assessing CLBP. Depending on the instruments used, pain severity can be measured on a bi-dimensional or one-dimensional scale.
Chronic Lower Back Pain Epidemiology Segmentation
The Chronic Lower Back Pain report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
- Chronic Lower Back Pain Total Prevalent Population
- Chronic Lower Back Pain Gender-Specific Prevalent Population
- Chronic Lower Back Pain Age-Specific Prevalent Population
- Chronic Lower Back Pain Severity-Specific Prevalent Population
- Chronic Lower Back Pain Type-Specific Prevalent Population
- Number of Chronic Lower Back Pain Patients on Prescription Medications by Different Class
- Number of Chronic Lower Back Pain Patients on Opioids by Low Dose, High Dose, and Overdose
Want to learn more? Request for sample @ Chronic Lower Back Pain Market Outlook
Chronic Lower Back Pain Treatment Landscape
The current major options for Chronic Lower Back Pain treatment include:
- NSAIDs
- Opioids
- Muscle relaxants
- Antidepressants
- Anticonvulsants
Chronic Lower Back Pain Market
- The Chronic Lower Back Pain market size was found to be USD 4,956.83 million in the 7MM in 2020.
- The United States accounted for 62% of the overall CLBP market size among the 7MM in 2020.
- The Chronic Lower Back Pain market size is anticipated to increase due to the launch of upcoming therapies such as Buprenorphine, Egalet-002, Tanezumab, Rexlemestrocel-L, Fasinumab, along with others.
For more information on the market outlook of CLBP, visit Chronic Lower Back Pain Market Size
Chronic Lower Back Pain Pipeline Therapies and Key Companies
- Buprenorphine (CAM2038): Braeburn Pharmaceuticals/Camurus
- Egalet-002: Egalet Corporation
- Tanezumab: Pfizer/Eli Lilly and Company
- Rexlemestrocel-L (MPC-06-ID): Mesoblast
- Fasinumab: Regeneron Pharmaceuticals/Teva Pharmaceutical
- ARRY-954: Array BioPharma/Asahi Kasei Pharma Corporation
- AXS-02: Axsome Therapeutics
- ALLOD-2: Allodynic Therapeutics
- ASP7962: Astellas Pharma
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
Chronic Lower Back Pain Key Companies: Braeburn Pharmaceuticals, Camurus, Regeneron Pharmaceuticals, Teva Pharmaceutical, Pfizer, Eli Lilly and Company, Mesoblast, Egalet Corporation, Axsome Therapeutics, Allodynic Therapeutics, Astellas Pharma, Grünenthal GmbH, Frontier Biotechnologies, DiscGenics, Yuhan Corporation, Semnur Pharmaceuticals, Stayble Therapeutics, AnGes MG, among others.
Chronic Lower Back Pain Key Pipeline Therapies: Buprenorphine, Egalet-002, Tanezumab, Rexlemestrocel-L, Fasinumab, AXS-02, ALLOD-2, ASP7962, ARRY-954, and others.
Chronic Lower Back Pain Segmentation: By Geography, By Chronic Lower Back Pain therapies
Analysis: Comparative and conjoint analysis of Chronic Lower Back Pain emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
| 1. | Key Insights |
| 2. | Chronic Lower Back Pain (CLBP) Market Overview at a Glance |
| 3. | Executive Summary |
| 4. | SWOT Analysis |
| 5. | Chronic Lower Back Pain (CLBP): Disease Background and Overview |
| 6. | Chronic Lower Back Pain Epidemiology Methodology |
| 7. | Chronic Lower Back Pain Epidemiology and Patient Population |
| 8. | Chronic Lower Back Pain United States Epidemiology |
| 9. | Chronic Lower Back Pain EU5 Epidemiology |
| 10. | Chronic Lower Back Pain Japan Epidemiology |
| 11. | CLBP Treatment Algorithm, Current Treatment, and Medical Practices |
| 12. | Proposed Guidelines for Chronic Lower Back Pain |
| 13. | Chronic Lower Back Pain Unmet Needs |
| 14. | Chronic Lower Back Pain Marketed Products |
| 15. | Chronic Lower Back Pain Emerging Therapies |
| 16. | Chronic Lower Back Pain Market Forecast Methodology |
| 17. | Chronic Lower Back Pain (CLBP): 7MM Market Analysis |
| 18. | Conjoint Analysis |
| 19. | Chronic Lower Back Pain United States: Market Outlook |
| 20. | Chronic Lower Back Pain EU-5 countries: Market Outlook |
| 21. | Chronic Lower Back Pain Japan Market Outlook |
| 22. | Case Reports |
| 23. | Chronic Lower Back Pain Market Drivers |
| 24. | Chronic Lower Back Pain Market Barriers |
| 25. | SWOT Analysis |
| 26. | Chronic Lower Back Pain Reimbursement and market access |
| 27. | Appendix |
| 28. | DelveInsight Capabilities |
| 29. | Disclaimer |
| 30. | About DelveInsight |
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
